Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.43 · Revenue $0.00 · 3 analysts
Est. EPS $-0.52 · Revenue $0.00 · 3 analysts
Est. EPS $-1.82 · Revenue $10000.00 · 5 analysts
Est. EPS $-0.50 · Revenue $0.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-103.7M | -16.5% | -37.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-70.5M | +3.8% | +3.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.1% | — | +153.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 28.66x | +43.4% | +58.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $476.2M | +46.2% | +95.8% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.83 vs -1.74 | -5.5% | -0.49 vs -0.43 | -14.2% |
| Revenue Surprise | $0 vs $10000 | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | Common Stock | D | 4,630 | $58.35 |
| Aug 17, 2026 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | Common Stock | D | 1,388 | $59.35 |
| Aug 17, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Stock Option (right to buy) | D | 5,000 | $2.48 |
| Aug 17, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Common Stock | A | 5,000 | $2.48 |
| Aug 17, 2026 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | Common Stock | D | 3,900 | $58.37 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Samuel S. Kintz | Co-Founder & Head of Pipeline | USD 956,094 | Male | 1986 | Active |
Helen Louise Collins | Chief Medical Officer | USD 726,420 | — | 1963 | Active |
Joseph Lyssikatos | Co-Founder & Research Fellow | USD 709,400 | — | 1965 | Active |
Richard A. Fair | CEO, President & Director | USD 672,656 | Male | 1969 | Active |
Benjamin Hohl | Chief Financial Officer & Head of Corporate Development | USD 667,894 | Male | 1989 | Active |
Damiette Smit | Vice President of Clinical Development | — | — | — | Active |
Anish Patel | Co-Founder & Chief Operating Officer | — | Male | 1981 | Active |
Galya D. Blachman | Chief Legal Officer & Head of Business Development | — | — | 1977 | Active |
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare ConferenceDate: Tuesday, Sept.
Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-competitive inhibitor, aiming for a differentiated, chronic-use profile in a sequential treatment paradigm. Phase 1 data show 61% MMR at 80 mg daily, with favorable safety and convenience for chronic administration, supporting potential in earlier-line CML settings.
BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the ENABLE Phase 1 clinical trial of ELVN-001 in an oral and a poster presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting, taking place September 9-12, 2026, at the George R.
BlackRock Inc. acquired a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,359,704 shares of the company's stock, valued at approximately $221,255,000. BlackRock Inc. owned 7.16% of Enliven Therapeutics at
Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML).
